key: cord-0897691-l505gwl8
authors: Patten, J.J.; Keiser, Patrick T.; Gysi, Deisy; Menichetti, Giulia; Mori, Hiroyuki; Donahue, Callie J.; Gan, Xiao; Valle, Italo do; Geoghegan-Barek, Kathleen; Anantpadma, Manu; Boytz, RuthMabel; Berrigan, Jacob L.; Hulsey-Stubbs, Sarah; Ayazika, Tess; O’Leary, Colin; Jalloh, Sallieu; Wagner, Florence; Ayehunie, Seyoum; Elledge, Stephen J.; Anderson, Deborah; Loscalzo, Joseph; Zitnik, Marinka; Gummuluru, Suryaram; Namchuk, Mark N.; Barabási, Albert-László; Davey, Robert A.
title: Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo
date: 2022-02-01
journal: bioRxiv
DOI: 10.1101/2021.04.20.440626
sha: 4f507ea50c75289d1607ae585b677ca8eb4bd714
doc_id: 897691
cord_uid: l505gwl8

Identification of host factors contributing to replication of viruses and resulting disease progression remains a promising approach for development of new therapeutics. Here, we evaluated 6710 clinical and preclinical compounds targeting 2183 host proteins by immunocytofluorescence-based screening to identify SARS-CoV-2 infection inhibitors. Computationally integrating relationships between small molecule structure, dose-response antiviral activity, host target and cell interactome networking produced cellular networks important for infection. This analysis revealed 389 small molecules, >12 scaffold classes and 813 host targets with micromolar to low nanomolar activities. From these classes, representatives were extensively evaluated for mechanism of action in stable and primary human cell models, and additionally against Beta and Delta SARS-CoV-2 variants and MERS-CoV. One promising candidate, obatoclax, significantly reduced SARS-CoV-2 viral lung load in mice. Ultimately, this work establishes a rigorous approach for future pharmacological and computational identification of novel host factor dependencies and treatments for viral diseases.

In December 2019, an unidentified pneumonia was reported in Wuhan, China, and by early January 2020, the causative agent had been identified as a novel coronavirus now called SARS-CoV-2. SARS-CoV-2, of the family Coronaviridae, is a single-stranded, positive-sense RNA virus with a genome of approximately 29kb 1,2 . SARS-CoV-2 is the third coronavirus in recent history to produce an epidemic, after SARS-CoV and MERS-CoV 3, 4 . The virus has rapidly spread across the world causing over 290 million cases globally of COVID-19, as of January 2022, resulting in more than 5.4 million deaths 5 and causing economic contraction, mass unemployment, disruption of education, and increasing poverty levels 6 . Fortunately, effective vaccines have become quickly available and are being distributed on an emergency basis.

However, given the emergence of more contagious and potentially pathogenic variants, and the need for more effective therapies for patients, the search for new therapeutics remains a priority 7, 8 . These efforts were launched by a series of repurposing screens of varying sizes. The largest was a screen of a 12,000 compound library, termed ReFRAME 9 , and a recently reported screen of a 3000 compound library by Ditmar et al 10 . Both studies identified PIKfyve inhibitors, numerous protease inhibitors (for example MG-132), several classes of kinase inhibitors and cyclosporin and analogues. While it was encouraging to see overlap between these studies, each also highlighted the interassay variability seen in evaluation of small molecule inhibitors of SARS-CoV-2 replication to date and the need for additional and more detailed studies.

Clinical successes to date have largely been confined to repurposed antivirals 11 , highlighting the need for further efforts to identify compounds with novel mechanisms of action and better define pathways and targets of interest for future SARS-CoV2 therapeutics. The current study focused on screening of the Drug Repurposing Hub (DRH) library, a collection of 6710 compounds highly enriched with molecules which have been FDA approved, entered clinical trials (4.8% Phase 1, 2.0% Phase 2, 7.5% Phase 3, 4.4% Phase 4), or have been extensively pre-clinically characterized 12 . The library comprises clusters of structurally related molecules that, with a well annotated database for host drug targets, provides a unique opportunity to capture preliminary structure-activity relationships of active molecules as well as identification of host targets of action that could be used to better design novel, specific therapeutics against SARS-CoV-2. The primary screen was the first to be conducted using multiple treatment doses at this scale, providing a data set that grades all compounds by activity from strongest to least active. These data were used to expand our previous computational studies in establishing SARS CoV-2 associated protein networks that may be enriched in host targets for future drug discovery efforts 13 . The most promising hits from the screening effort were assessed for efficacy in a series of orthogonal assays conducted in human cell lines (Huh-7 and A549 cells), and human primary cell-based tissue models. Our studies confirmed the activity of several previously identified (inhibitors of PIKfyve, cathepsins, protein synthesis) as well as novel compound classes. The most promising small molecule treatment to emerge from the screen, obatoclax, demonstrated consistent activity across all cell-based assays and virus strains tested, including against MERS-CoV and reduced SARS-CoV-2 titers by up to 10-fold in a mouse infection model using clinically achievable compound exposures.

The DRH compound library (Fig. 1A) was initially evaluated using an immunofluorescencebased assay to detect SARS-CoV-2 N protein expression. The screen was followed by computational analysis to prioritize the most potent for follow up in mechanistic assays evaluating impact on cell entry, genome replication and egress of progeny viruses as well as evaluation in primary human cell models (Fig. 1B) . In order to capture multiple rounds of viral replication 14 and obtain strong N protein staining, the primary screen was conducted for [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] hours. While suitability of other cell types was evaluated for screening, VeroE6 cells, derived from African green monkey kidney cells, supported the most robust and consistent infection compatible with high-throughput screening at high biocontainment. Using automated analysis of stained cells (Fig. 1C , upper) the assay gave an average >80-fold difference between infection of untreated cells and those treated with a previously reported inhibitor of SARS-CoV-2 replication, the protease inhibitor, E64d 15 and yielded an assay Z' of 0.6, indicating suitability for a high throughput screen 16 (Fig. 1C, lower) .

To identify compounds with concentration responses and to grade each for potency, four doses of each compound were tested, ranging from 8 nM to 8 μ M in 10-fold increments. Compounds were initially grouped using a log-logistic regression for viral load (Wald test; padj < 0.01;

Bonferroni correction) to classify compounds (Table S1 ) on potency as strong (80% viral reduction, or Z score > 2.5), weak (50-80% viral reduction, Z score 1.5-2.5) inactive (padj >= 0.01), or cytotoxic (>60% cell loss by nuclei count and Wald test on a log-logistic regression for cell count; padj < 0.01; Bonferroni correction).We identified 172 (2.56%) strongly active, 217 (3.23%) weakly active and 1.6% as cytotoxic (examples shown in Fig. 1D ). The data is deposited in the DRH database: https://www.broadinstitute.org/drug-repurposing-hub with active compounds summarized in Fig. 2A .

To reveal the structural characteristics that defined active compounds, structures were encoded using Morgan Fingerprints (around molecular heavy atoms up to radius 3, and hashed each molecular fingerprint to a binary vector of 8, 192 bits, Table S2 ) and similarity searches performed. While the library showed diverse structural characteristics, active molecules showed a higher median of active bits ( class. Of these, some have been previously reported, such as aminoquinolines (amodiaquinerelated), nucleosides (Remdesivir-like) and phenothiazines (chlorpromazine-like, antipsychotic drugs) but others have not been previously discussed in detail (pyrimidyl-indolines, similar to GSK2606414), azaspiranes, phenylpiperidines, benzodiazines, phenylpropanoids and steroid lactones (cardiac glycosides).

We next evaluated if the drugs that presented structural similarity were also targeting the same or homologous proteins. For that, we selected all pairwise molecule structures with Jaccard similarity higher than 0.5 for which both had at least one protein target described in the Broad Library. We next calculated the gene overlap of those drugs, and found that out of the 32 pairwise similar drugs, 29 compound pairs shared at least one protein target (Fig. S4 ). For the remaining 3 pairs, we compared the protein target sequences and found each were related. Only one pair (sertraline and indraline) share structural similarity without sharing protein target similarity. This analysis suggests that for these related pairs of molecules, activity may correspond to homologous or similar protein targets.

Of the 6710 compounds, 4,277 had attributable host targets annotated in the DRH database. GO enrichment showed a similar profile with active drugs enriched for processes related to rRNA, microtubules, collagen and proteoglycan binding, and GPCR receptor activity, GTP metabolism, viral transcription processes, ion channel function and protein folding (Table S3 ). It is interesting that angiotensin-related drugs were identified as SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) as a receptor. While a topic of interest early in the pandemic, patients already taking such drugs have not shown a beneficial outcome 18 . Furthermore, effort was made to prevent oversampling of promiscuous compounds and over-represented targets but GPCRtargeting compounds are one of the most abundant drug classes and, thus, must be interpreted with caution. Fisher's exact test was used to identify if active compounds were enriched for known drug-targets. Of the 389 active compounds, 813 targets were identified and only 51 targets appeared enriched (Fisher's exact test; p < 0.05). These were related to sodium ion export, membrane repolarization, regularization of cardiac conduction (Table S4 ). The drugtarget network analysis for these compounds revealed two large modules of drugs sharing its targets, comprising 61 drugs, and 119 targets, and 43 drugs and 66 targets. We also identified 105 additional smaller modules suggesting compounds targeted a discrete group of host targets ( Fig. 2D ).

To understand where these drug-targets are found in a human protein-protein interaction network, we first calculated the largest connected component (LCC) targets in each outcome class and the significance of the module size using a degree-preserving approach 19 , preventing the same high degree nodes being selected repeatedly. We find that the LCC of the drug targets are statistically significantly larger than random for strong (149; 126.02 ± 10.91; Z-Score 2.11) and weak (211; 173.84 ± 15.18; Z-Score 2.45) classes. The combined class was also significant (311; 277 ± 18.69; Z-Score 1.8) (Fig. S5 ). Taken together, the analysis suggests clustering of drug targets within the interaction network.

To better understand the relationships of active compounds the network separation between targets of each category was computed (Fig. 2E ). Similar to our previous study 20 Interestingly, when we asked if targets were related to identified SARS-CoV-2 host protein interactions 21 we found, similar to our previous study 20 , that the relative network proximity of each target module to the COVID-binding proteins is predictive of efficacy. Active compounds have z-scores close to zero ( Fig. 2F ) whereas, inactive compounds have a much stronger positive proximity z-score, indicating their targets are far from COVID-binding proteins than random expectation. Taken together, these data show that active and inactive compounds target distinct network neighborhoods in the human protein-protein interaction network, and their network proximity to the COVID-binding proteins is predictive of drug efficacy.

In addition to analyzing gene targets, 6,150 of the compounds were annotated for mechanism of action in the DRH 12 . Using this information, we checked for over-and under-represented MOA that could be driving the drug response using a ߯ ଶ -test (p < 0.05, FDR-BH). Here, inhibitors of mTOR, antimalarial agents, ATPase, HSP, bromodomain, and tubulin polymerization were significantly enriched. Furthermore, mapping of compounds to the Anatomical Therapeutic Chemical Classification (ATC) drug categories 22 and chemical taxonomy identified compound classes that were over-represented in the hits (Table 1) . These included previously identified classes of compounds active against SARS-CoV-2 in vitro, including phenothiazines, benzothiazines, and other antipsychotic agents, as well as new classes such as PERK inhibitors and the cardiac glycosides. Each of these classes were also found clustered in the structural analysis ( Fig. 2C ) supporting the relationship between drug class and host targets.

Based on performance in the primary screen and compound classification using the structural similarity clustering and ATC classifications, 40 representative compounds were chosen for detailed potency determination, and mechanistic analysis. The compounds were initially rescreened in VeroE6 cells to confirm activity before evaluation in human cell lines and timing was set to capture limited virus replication. In general, most compounds yielded EC 50 values similar to that expected from the primary screen potency determination (Table 2 , third column, Figure S6 and examples in Fig. 3A ). For some compounds, such as methotrexate, a complex inhibition pattern was observed upon dose titration, being inhibitory at low doses but reaching a plateau above the 50% infection level and so an EC 50 was not calculated.

Compounds were then evaluated using a human cell line, Huh7, that is intrinsically susceptible to Differences were also observed for two each of the HSP90 and BET protein inhibitors that were classed as weak inhibitors in Vero cells. For the HSP90 inhibitor AT13387, activity at the highest dose tested (150 nM) was observed. BET inhibitors, BET-BAY-002 and mivebresib, were also active. Overall, such changes in activity suggest differences in dependency on BET and HSP90 proteins or drug action in Vero versus human Huh7 cells.

The impact of compounds on virus mRNA production was measured using a FISH assay targeting RNA production from the viral subgenomic promoter that controls expression of structural proteins (Fig. 3B ) and image analysis to score replication efficiency. In general, activity in this assay reflected that seen in the qPCR-based assay with potency typically being within 3-fold of each other ( Table 2 ). The DHODH inhibitor, BAY-2402234, was the most potent, inhibiting infection by 50% at 10 nM. The protein synthesis inhibitors, emetine, harringtonine, and homoharringtonine, were equally active, blocking >50% RNA production at well the mTOR and BCL inhibitors, omipalisib and obatoclax, respectively. Cardiac glycosides, proscillaridin and ouabain, were also active at 50 and 150 nM, respectively. Of note was the large difference in activity of harringtonine and homoharringtonine being over 5 to 8-fold more potent in the virus genome release assay over the RNA production assay, which would be consistent with disruption of virus assembly and may reflect the need for balanced stoichiometry of structural proteins easily disrupted by protein synthesis inhibition. Similarly, differences were noted for compounds that inhibited genome release from cells in the qPCR assay but had negligible impact on the viral mRNA signal. These compounds were the DHFR inhibitor, pralatrexate, the COX inhibitor, talniflumate, the BET inhibitors, BET-BAY-002 and mivebresib, and the methyltransferase inhibitor, BIX-01294, suggesting that each also worked to disrupt packaging of viral genomes into new virus particles and/or their release into the culture medium. A recent report indicated that methotrexate, a paralog of pralatrexate, can block release of SARS-CoV-2 genomic RNA into the culture medium 23 . For the COX inhibitor, talniflumate, COX activity has also been shown to be important for packaging of pseudorabies genomes into capsids 24 . Furthermore, BET proteins were identified as interacting with SARS-CoV-2 E, a protein important for maturation and release of virions from cells 21 and were identified as a COVID-network associated drug target class l analysis in our computational analysis (Fig. 2E , F). To our knowledge, a role for methyltransferases in production and packaging of virus genomes has not been reported and will require additional work to understand its role.

We next sought to evaluate the impact of compounds that displayed the most potent effects on 

Recently, it was reported that many compounds from repurposing libraries showing antiviral activity act by by inducing phospholipidosis (PLD) and disrupting cell lipid metabolism 28, 29 .

Since, some of the compounds of interest had potentially protonatable amines, a hallmark of PLD inducers, we evaluated each by NBD-PE staining, but found that none induced PLD ( Fig.   S8 ) even when tested at >100 times higher than their anti-viral active concentrations. We conclude that the compounds act through non-PLD mechanisms.

Four of the most active treatments were evaluated using primary lung and gastrointestinal multicellular models. While COVID19 causes severe respiratory distress, several studies have reported over half of patients also suffer from gastrointestinal symptoms, including diarrhea, abdominal pain, and vomiting. The gut is also a prominent site for virus replication 30 . Human donor-derived stratified epithelial cell models representing the airway and gut were obtained commercially 31 . Similar to previous reports 32 , infection in the lung model was variable between batches and not easily used for compound evaluation. However, the gastrointestinal model cells expressed ACE2 mRNA and protein (Fig. S9 ) and gave robust, uniform infection (Fig. 5A ). By morphology, the infected cells appeared to be epithelial. The compounds tested in this model,

including Remdesivir as an active control 33 were used at the VeroE6 EC 90 concentration.

Emetine, GSK2606414 and obatoclax were as effective as Remdesivir, preventing >80% of cell infection. Proscillaridin was less effective, showing inhibition ranging from 50 to 80%. These observed differences helped further refine compound activities, with the most promising showing consistent activity across cell lines and human tissue models.

Obatoclaxdemonstrated potent and consistent antiviral activity across al in vitro assessments, and has been reported to have favorable pharmacokinetics and tolerability in mice 34 . We used K18-hACE2 transgenic mice, which express recombinant human ACE2 (hACE2) protein under control of a K18 cytokeratin promoter to evaluate each compound as a treatment for disease.

Others have shown that challenge by the intranasal route results in virus replication in the lungs, heart, brain, kidneys and gut 35, 36 with titers increasing over 2-3 days and then subsiding after day 5 in most tissues, but with titers in the brain continuing to rise to >10 8 pfu/g tissue. The latter is thought to result in severe symptoms, which may not be relevant to human disease outcomes. To focus on treatments effective in the respiratory system, animals were treated daily for 4 days after virus challenge and virus load in the lungs was measured. Vehicle control animals reached titers consistent with previously reported levels of 1-3 x 10 6 FFU/g lung tissue. At a dose of 3 mg/kg, obatoclax gave a consistent and significant reduction in average virus load by >88% in both male and female mice (p=0.0028). For two of the female treated mice, lung virus load fell below the limits of detection of the assay, although one did have trace amounts of detectable virus (Fig. 5B ). This suggests that obatoclax may be useful as a COVID-19 treatment candidate.

Lastly, we tested efficacy of each of the potent hits against Beta and Delta variants of SARS-CoV-2 ( Fig. 5C ) and the distantly related MERS-CoV virus (Fig. S10) . Surprisingly, the Beta variant showed several differences in susceptibility to drug treatment. Of note, Omipalisib appeared to elevate infection, while A485 and BAY-2402234, showed little activity. In contrast, the Delta variant showed a similar profile to that seen for the Washington strain used for the initial screening. This suggests that the Beta variant may have a different dependency profile on cell processes disrupted by the compounds.

While multiple vaccine candidates are now available, alternative therapeutic avenues will be needed to control COVID19 disease. Here, we Obatoclax consistently showed potent antiviral activity across all in vitro systems, as well efficacy in the mouse disease model. The 10-fold decrease in lung titers is promising given that a similar reduction of virus load has been associated with decreased mortality in COVID-19 patients 37 . Obatoclax was originally developed as a broadly acting BCL-2 homology domain 3

inhibitor for cancer treatment 38 with activities including inducing apoptosis and elevating autophagy 38,39 , each potentially virucidal outcomes. However, the 7 other BCL-2 inhibitors that we tested were weak or inactive, indicating that BCL-2 inhibition is less likely to be a specific mechanistic target. A previous report showed inhibition of endosomal acidification by obatoclax but not by other BCL-2 inhibitors and explained inhibition of infection by alphaviruses through preventing pH-dependent endosomal escape 27 . Consistent with this mechanism, the pseudotype infection assay (Fig. 4) , showed obatoclax partially blocking infection for the SARS-CoV-2 pseudotype. However, another report showed that influenza virus, which also requires endosomal acidification to infect cells, was unaffected by obatoclax 40 . Taken together, while SARS-CoV-2 requires acidified endosomes for cell entry and entry is partly blocked by obatoclax, an additional entry-independent modality may be involved in infection inhibition and will require more detailed characterization.

One of the most potent classes of inhibitors identified were the cardiac glycosides, such as proscillaridin, that have Na+/K+ channel blocking activity. These steroid- Another class of compounds that have not been reported to affect SARS-CoV-2 infection are the BET inhibitors. These compounds, like mivebresib, affected SARS-CoV-2 infection in both cell types tested and were identified in our protein network analysis (Fig. 2) . Previous work showed two of the four BET proteins, BRD2 and BRD4, were bound by virus E protein 21 . The E protein is involved in assembly and budding of newly formed coronaviruses from the cell. Our finding that the BET inhibitors block viral egress (Table 4) is consistent with this mechanism of action.

Being able to identify such egress inhibitors also serves to demonstrate the utility of the In summary, using a high-throughput drug screen, we have elucidated both potent antivirals and host factors strongly entwined in the SARS-CoV-2 lifecycle. We aimed here to provide both a more detailed understanding of how the virus hijacks host machinery to replicate, as well as methods to interrupt these dependencies. By making all the data publicly available through the DRH we anticipate that both the active and inactive compounds will inform future studies. Due to the pressing need for antivirals to combat COVID-19, our findings will aid scientists and clinicians with identifying, prioritizing, and testing novel therapeutics, and help alleviate the burden this pandemic has placed on our society. While these findings are encouraging, and suggest drug-repurposing as a productive approach for rapidly identifying treatments, it is important to be mindful that novel drug-disease interactions may occur when used for a different purpose, necessitating prospective clinical trial assessments.

Cell and virus cultivation. 

To verify the results of the initial screen, small molecules were chosen for full dose-response evaluation based on initial potency and drug class. The night before the screen, 2x10 4 Vero E6 cells were seeded in each well of a 96 well plate. As before, compounds were diluted in culture medium and incubated on cells for a minimum of 1 hour, with a range of final concentration from 4 µM to 0.2 nM in a three-fold dilution series. Infection, fixation, staining, and analysis were performed as described above. The assay was performed in triplicate.

Compounds that yielded consistent dose-responses were further evaluated using qPCR to detect virus genomes and in situ virus mRNA detection as orthogonal assays. They were also evaluated in the intrinsically infectable human cell line, Huh7.

To measure virus assembly and release, qPCR was used to detect viral genomic RNA in the cell culture supernatant using a method modified from Suzuki et al. 51 Briefly, Hoechst-stained nuclei were expanded to encompass approximate cell area and PLD, defined as GFP signal above background, was classified as an object. PLD falling within the cell area was attached to each cell to define a new object, and the total intensity of PLD-positive cells in each image was measured. PLD was normalized to fold change over DMSO treatment and compared to amodiaquine (a known PLD inducer) to determine PLD activity.

Human small intestine epithelial cells were obtained and used to produce a reconstructed tissue model as described previously 31 

The evening prior to infection, 1.5x10 4 A549 cells expressing ACE2 or DPP4 were seeded into 96 well plates. Compounds were dosed out at three concentrations-their respective IC90s, plus 5-fold above and below. After a one hour incubation, virus was added to the pretreated cells Computational methods.

In order to classify the drug response by potency, the infection efficiency and total cell nuclei count were normalized per plate to the average of in-plate untreated control wells. Infection efficiency was calculated as the ratio of total infected cells divided by the total cell nuclei count per well. Wells with an infection efficiency greater than one were removed from further analysis as these indicated a fault in the imaging. Treatments that resulted in >60% loss of cell nuclei compared to untreated controls were flagged as being potentially cytotoxic and were deprioritized. Treatments resulting in >80% cell loss were not evaluated as the virus MOI would be significantly altered together with a loss in calculation accuracy.

The classification of the drug-response outcomes was performed using a drug response curve (DRC) model. We used the R package drc 56 to calculate the DRCs using a log-logistic model that estimates four parameters (Hill slope, IC50, min, and max). Each drug-response was classified by inspecting cell nuclei count, and then evaluating the drug effect on the inhibition of viral infection efficiency. Each drug-response was classified in two steps: first inspecting toxicity by nuclei count and then evaluating the drug effect on the inhibition of viral proliferation using the model given by Eq. 1.

Eq Treatments that showed cell nuclei loss greater than infection inhibition for at least half of doses tested were classified as being potentially cytotoxic and were de-prioritized for follow-up studies.

All outcomes were manually inspected in order to validate the two step-model and annotation

compared to the computational model derived outcome.

Using all targets within each drug category, we performed a GO enrichment analysis in the biological process and molecular function mode using the enrichR tool.

Using genes that were statistically significantly enriched in each category, we built a bipartite network, from drugs and targets for each category.

In order to understand where the drug-targets were placed in a human protein-protein interaction network, we first calculated the largest connected component (LCC) of each drug category and calculated the significance of the module size using a degree-preserving approach 19 , preventing the same high degree nodes being selected repeatedly by choosing 100 bins in 1,000 simulations.

For that purpose, the R package NetSci was used.

To understand if there was an enrichment of any gene as a drug target in each category, we used a Fisher's exact test, and considered a gene to be enriched in any category if its p-value is lower than 0.05 (complete results can be found in Table S3 ). For each set of genes, we performed a biological function enrichment using Enrichr 57 .

We aggregated the targets of the compounds classified in the different outcome categories (e.g., strong, weak) and performed pathway enrichment analysis (Reactome) using the R package ReactomePA 58 .

We retrieved mechanism of action annotations for 6,150 drugs from the Drug Repurposing Hub . 12 . For each mechanism of action, we checked over-or under-representation of drugs in the different drug outcomes (e.g., strong, weak) by using a Chi-Square test (p < 0.05, FDR-BH).

To evaluate structure similarity between molecules, similarity searches and clustering were performed using molecular fingerprints (FPs). The python package RDKit 59 was used to standardize SMILES and InChIKeys associated with each drug tested in the experiments, and generate Morgan FPs (also known as extended-connectivity fingerprints). All molecular substructures up to radius 3 were assigned to unique identifiers and hashed to vectors of 8, 192 bits in order to capture fragments of bigger size and reduce the potential bit collision. For all molecules with experimental outcome, structural similarity was quantified by Jaccard (or Tanimoto) similarity. We further leveraged the Jaccard metric to reduce the dimensionality of the bit vector representation to 3D with UMAP 17 . In the bit representation of Morgan FPs each bit is mapped to multiple structural fragments appearing in molecules. We evaluated the significance of each bit for ligand binding by calculating the average number of non-hydrogen atoms in the associated fragments, finding that in the overall database the median size of the expected chemical fragment associated with each bit is 9. The enrichment of each experimental class in active bits (hypergeometric test, BH multiple testing correction with ߙ ൌ 0 . 0 5 ) was then calculated. As shown in Figure S1 , the significant bits for strong drugs appear to be moderately bigger and potentially more meaningful for binding, with 22 bits in the Strong Class with average size greater than the database median, compared to only 1 bit for 'Cyto', cytotoxic class.

Aside from the tests described above and within the text, statistical significance between treatments and across experiments was calculated using Student's T test or one-way ANOVA 

A new coronavirus associated with human respiratory disease in China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Koch's postulates fulfilled for SARS virus

Middle East respiratory syndrome

An interactive web-based dashboard to track COVID-19 in real time

The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

Detection of B.1.351 SARS-CoV-2 Variant Strain -Zambia

First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Drug repurposing screens reveal cell-type specific entry pathways and FDA approved drugs active against SARS-Cov-2

Early Returns on Small Molecule Therapeutics for SARS-CoV-2

The Drug Repurposing Hub: a next-generation drug library and information resource

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Network-based in silico drug efficacy screening

Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

anatomical therapeutic chemical classification system (ATC)

Methotrexate inhibits SARS-CoV-2 virus replication "in vitro

Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus

Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges

Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide

Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis

SARS-CoV-2 productively infects human gut enterocytes

Human small intestinal organotypic culture model for drug permeation, inflammation, and toxicity assays

SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK

Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells

Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses

Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity

Proscillaridin A induces apoptosis and inhibits the metastasis of osteosarcoma in vitro and in vivo

Cardiac glycoside/aglycones inhibit HIV-1 gene expression by a mechanism requiring MEK1/2-ERK1/2 signaling

Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine

Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Realtime Quantitative Polymerase Chain Reaction

smiFISH and FISH-quant -a flexible single RNA detection approach with superresolution capability

CellProfiler 3.0: Next-generation image processing for biology

HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction

Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells

Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization

Get Your Atoms in Order--An Open-Source Implementation of a Novel and Robust Molecular Canonicalization Algorithm